Pure EPA Should Be Preferred Over EPA+DHA Combinations for Cardiovascular Risk Reduction in High-Risk Patients
In adults with hypertriglyceridemia (150-499 mg/dL) who have established cardiovascular disease or are at increased risk for ASCVD while on statin therapy, pure EPA (icosapent ethyl) should be used instead of EPA+DHA combinations.
Clinical Situations Favoring Pure EPA
Primary Indication: Cardiovascular Risk Reduction
The 2025 AACE guidelines provide clear directional guidance: pure EPA (icosapent ethyl) is conditionally recommended for cardiovascular risk reduction, while EPA+DHA combinations are specifically recommended against in the same patient population 1.
Key patient criteria for pure EPA:
- Triglycerides 150-499 mg/dL (fasting) or ≥175 mg/dL (non-fasting)
- Already on statin therapy
- Established ASCVD OR diabetes with additional risk factors OR high-risk primary prevention
- Goal: reduce cardiovascular events (myocardial infarction, unstable angina)
Why Pure EPA Over EPA+DHA?
Cardiovascular outcomes evidence:
- Pure EPA (4g/day icosapent ethyl) demonstrated significant reductions in cardiovascular events in REDUCE-IT and JELIS trials 1, 2, 3
- EPA+DHA combinations (1.8g/day) showed no clinically meaningful reduction in cardiovascular events or mortality in ASCEND, VITAL, STRENGTH, and OMEMI trials 1, 4, 3
- A 2026 meta-analysis confirmed that among blinded cardiovascular outcomes trials, 4g/day icosapent ethyl is the only formulation independently associated with reduced cardiovascular events 5
Lipid profile considerations:
- EPA+DHA combinations increase LDL-C levels, which can confound dyslipidemia management 6, 7, 8
- Pure EPA (icosapent ethyl) either maintains or slightly reduces LDL-C 8
- Both formulations lower triglycerides, but the LDL-C effect differentiates them clinically 6
When EPA+DHA May Be Considered (Limited Evidence)
Severe hypertriglyceridemia (≥500 mg/dL):
- Insufficient evidence exists to recommend for or against either formulation 1
- Primary goal shifts to pancreatitis prevention rather than cardiovascular risk reduction
- Both prescription omega-3 formulations can lower very high triglycerides 9, 4
- In this setting, choice may be based on availability and tolerability rather than cardiovascular outcomes
Non-cardiovascular indications:
- Metabolic syndrome features: DHA may preferentially increase HDL-C compared to EPA 6
- However, DHA also increases total cholesterol, LDL-C, and insulin levels 6
Critical Implementation Details
Dosing specificity matters:
- Cardiovascular benefit requires 4g/day of pure EPA (icosapent ethyl), not lower doses 1, 3
- Over-the-counter omega-3 supplements (typically <1g EPA+DHA) have not demonstrated cardiovascular benefit 2, 4
- Prescription products and dietary supplements are not interchangeable 7
Safety considerations for both formulations:
- Small increased risk of atrial fibrillation 1
- Small increased risk of major bleeding 1
- Shared decision-making should address these potential harms against cardiovascular benefits
Common Pitfalls to Avoid
Do not substitute EPA+DHA for pure EPA when the goal is cardiovascular risk reduction—the evidence bases are distinct and outcomes differ 3, 7
Do not use over-the-counter omega-3 supplements as substitutes for prescription formulations—they lack standardization, may contain oxidized fatty acids, and have not demonstrated cardiovascular benefit 7
Do not prescribe EPA+DHA combinations in statin-treated patients with moderate hypertriglyceridemia seeking cardiovascular risk reduction—guidelines specifically recommend against this 1
Do not ignore the LDL-C increase with EPA+DHA products, which may require additional lipid management 6, 8
Algorithmic Approach
For patients with triglycerides 150-499 mg/dL on statin therapy:
- Established ASCVD or high cardiovascular risk → Pure EPA (icosapent ethyl) 4g/day 1
- Goal is cardiovascular event reduction → Pure EPA only 3
- Concerned about LDL-C increase → Pure EPA (avoids LDL-C elevation) 8
For patients with triglycerides ≥500 mg/dL:
- Primary goal is pancreatitis prevention → Either prescription formulation acceptable 1
- Insufficient evidence to prefer one over the other for this indication 1
The 2026 ACC/AHA guidelines and 2025 AACE guidelines converge on this evidence-based distinction: pure EPA has proven cardiovascular benefits in appropriate populations, while EPA+DHA combinations have consistently failed to demonstrate such benefits in contemporary trials with adequate background statin therapy 9, 4.